ArticleDiscover oncology2025
Mechanistic role of miR-375 in regulating PDPK1 to promote progression of small bowel neuroendocrine tumors: a silico analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of small bowel neuroendocrine tumors (SBNETs) is steadily increasing, new therapies are urgently needed to prolong the overall survival of patients.
objectiveThis study aimed to identify diagnostic and therapeutic candidate markers for SBNETs.
methodsExpression profiles of miRNAs were collected from GSE70534, and GSE103317, that of mRNAs were collected from GSE65286. Differentially expressed genes (DEmiRs, DEmRs) were analyzed between SBNETs and controls. Enrichment and coexpression analyses were carried out for DEmRs. XGBoost algorithm was used to screening feature miRNAs. Module genes in SBNETs-related pathways were selected to construct regulated network for feature miRNAs. Drug targeting prediction and immune environment evaluation were identified.
resultsA total of 57 common DEmiRs with the same direction of expression were identified. Hsa - miR - 375, hsa - miR - 107, hsa - miR - 1180, hsa - miR - 330 - 3p, and hsa - miR - 328 were identified as feature miRNAs. Among the target genes of feature miRNAs, PDPK1 was the correlation between PDPK1 and the target of Lutetium-177 (177Lu)-DOTATATE was the largest, which were regulated by miR - 375. Additionally, PDPK1 showed correlations with eosinophils, cytotoxic cells, and checkpoints in SBNETs.
conclusionsFive feature miRNAs may have a good diagnostic role for the SBNETs. MiR - 375 regulated PDPK1 may serve as an effective therapeutic candidate marker for SBNETs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.